ALNY:NASDAQ
Alnylam Pharmaceuticals, Inc.
$255.05
arrow_downward
-1.94%(-5.05) 1D
Sep 9, 10:19:00 AM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNY...
Open
$257.07
High
$261.98
Low
$254.51
Mkt. cap
34.23B
Avg. vol.
2.21M
Volume
220.36K
P/E ratio
43.54
52-wk high
$495.55
52-wk low
$197.81
EPS
$5.88
Beta
0.31
Shares outstanding
133.81M
No. of employees
2K
Open
$257.07
High
$261.98
Low
$254.51
Mkt. cap
34.23B
Avg. vol.
2.21M
Volume
220.36K
P/E ratio
43.54
52-wk high
$495.55
52-wk low
$197.81
EPS
$5.88
Beta
0.31
Shares outstanding
133.81M
No. of employees
2K
News stories
From web sources and news partners
GuruFocus
·
21 hours ago
ALNY Maintained by Jefferies -- Price Target Raised to $260
Investing.com
·
1 day ago
Alnylam at Wells Fargo conference: TTR growth stays on track
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.